Stefan H. Hohnloser
Goethe University Frankfurt
Internal medicineCardiologyRandomized controlled trialHazard ratioSinus rhythmSudden cardiac deathWarfarinImplantable cardioverter-defibrillatorAmiodaroneHeart failureDabigatranAtrial fibrillationElectrocardiographyHeart diseaseIn patientAnesthesiaMyocardial infarctionStrokeMedicineEjection fraction
Publications 497
#1Alexander P. Benz (Population Health Research Institute)H-Index: 3
#2Stefan H. Hohnloser (Goethe University Frankfurt)H-Index: 89
#1Uwe ZeymerH-Index: 72
#2Orly LeivaH-Index: 8
Last. Christopher P. CannonH-Index: 168
view all 16 authors...
Aims To investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) vs warfarin triple therapy in patients with atrial fibrillation undergoing PCI for ST elevation myocardial infarction (STEMI). Methods and results In RE-DUAL PCI, 305 patients with STEMI were randomised to dabigatran 110 mg (n=113 versus 106 warfarin) or 150 mg (n=86 versus 84 warfarin). Primary endpoint was time to first major or clinically relevant non-major bleedi...
1 CitationsSource
#1Anne B. Curtis (UB: University at Buffalo)H-Index: 66
#2Emily P. Zeitler (Dartmouth–Hitchcock Medical Center)H-Index: 13
Last. Stefan H. Hohnloser (Goethe University Frankfurt)H-Index: 89
view all 7 authors...
AIMS Age and sex may impact the efficacy of antiarrhythmic drugs on cardiovascular outcomes and arrhythmia recurrences in patients with atrial fibrillation (AF). We report on a post hoc analysis of the ATHENA study (NCT00174785), which examined cardiovascular outcomes in patients with non-permanent AF treated with dronedarone vs. placebo. METHODS AND RESULTS Efficacy and safety of dronedarone were assessed in patients according to age and sex. Baseline characteristics were comparable across subg...
#1Sigrun Halvorsen (University of Oslo)H-Index: 34
#2Søren Paaske Johnsen (AAU: Aalborg University)H-Index: 75
view all 12 authors...
Aims null Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral anticoagulants compared with warfarin in oral anticoagulation-naive patients with atrial fibrillation (AF). null Methods and results null This historical cohort study included 219,545 AF patients (median age, 74 years; 43% women; mean CHA2DS2-VASc score 3.3) initiating apixaban, dabigatran, rivaroxaban, or warfarin in Denmark, Norway, and Swe...
#1Gregory W. Albers (Stanford University)H-Index: 122
Last. Derk W. KriegerH-Index: 34
view all 13 authors...
Occult atrial fibrillation (AF) is a leading cause of stroke of unclear cause. The optimal approach to secondary stroke prevention for these patients remains elusive. The term embolic stroke of undetermined source (ESUS) was coined to describe ischemic strokes in which the radiographic features demonstrate territorial infarcts resembling those seen in patients with confirmed sources of embolism but without a clear source of embolism detected. It was assumed that patients with ESUS had a high rat...
#6Camm (St George's, University of London)
Aims null Using a pre-planned post hoc analysis of patients included in X-VeRT, we evaluated predictors of sinus rhythm at 6 weeks after planned cardioversion. null Methods and results null Receiver operating characteristic curves and logistic regression models were used to evaluate continuous and categorical variables as predictors of sinus rhythm 6 at weeks from cardioversion (end of study). The primary analysis was performed in successfully cardioverted patients with an evaluable electrocardi...
#1David Eccleston (University of Melbourne)H-Index: 13
#2Joseph M. Kim (Brigham and Women's Hospital)
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 13 authors...
Background The RE-DUAL PCI trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual therapy with dabigatran and a P2Y12 inhibitor, either clopidogrel or ticagrelor, reduced the risk of bleeding without an increased risk of thromboembolic events as compared to triple therapy with warfarin in addition to a P2Y12 inhibitor and aspirin. What remains unclear is whether this effect is consistent between males and females un...
#1Benjamin E Peterson (Brigham and Women's Hospital)H-Index: 4
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 167
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 16 authors...
Abstract Objectives The aim of this study was to explore the early versus late benefits and risks of dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial. Background Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk fo...
3 CitationsSource
#1Jordi Heijman (UM: Maastricht University)H-Index: 25
#2Stefan H. Hohnloser (Goethe University Frankfurt)H-Index: 89
Last. A. John Camm (St George's, University of London)H-Index: 114
view all 3 authors...
Atrial fibrillation (AF) remains a highly prevalent and troublesome cardiac arrhythmia, associated with substantial morbidity and mortality. Restoration and maintenance of sinus rhythm (rhythm-control therapy) is an important element of AF management in symptomatic patients. Despite significant advances and increasing importance of catheter ablation, antiarrhythmic drugs (AADs) remain a cornerstone of rhythm-control therapy. During the past 50 years, experimental and clinical research has greatl...
2 CitationsSource
#1Alexander P. Benz (Population Health Research Institute)H-Index: 3
#2John W. Eikelboom (Population Health Research Institute)H-Index: 121
Last. Stuart J. Connolly (Population Health Research Institute)H-Index: 140
view all 9 authors...
Background AVERROES, a randomized controlled trial in high-risk patients with atrial fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of apixaban compared with aspirin. At the conclusion of the double-blind phase, an open-label extension was initiated to allow study participants to receive apixaban until it became locally available. This study reports outcomes of patients on apixaban during the open-label extension. Methods Rates of stroke or systemic e...
1 CitationsSource